Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 11/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711628 | 0.95 | GRIA4 (0.48) | GRIA4CA1CA2GRIA1 | |
| SCHEMBL13255710 | 0.95 | GRIA4 (0.48) | GRIA4CA1CA2GRIA1 | |
| SCHEMBL4295879 | 0.92 | GRIA4 (0.46) | GRIA4CA1CA2GRIA1CA12 | |
| SCHEMBL4295881 | 0.92 | GRIA4 (0.46) | GRIA4CA1CA2GRIA1CA12 | |
| SCHEMBL5186189 | 0.89 | GRIA4 (0.54) | GRIA4GRIA1 | |
| SCHEMBL5186065 | 0.89 | GRIA4 (0.43) | GRIA4CA1CA2 | |
| SCHEMBL5769048 | 0.89 | GRIA4 (0.42) | GRIA4CA1CA2GRIA1CA12 | |
| SCHEMBL13663202 | 0.88 | GRIA4 (0.43) | GRIA4CA1CA2GRIA1 | |
| SCHEMBL5642905 | 0.88 | GRIA4 (0.43) | GRIA4CA1CA2EPHX2NR1H4 | |
| SCHEMBL5186185 | 0.86 | GRIA4 (0.56) | GRIA4GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | GRIA4 17/4885CA1 307/4885CA2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.